Dichotomous and stable gamma delta T-cell number and function in healthy individuals

Adult Cytotoxicity, Immunologic Male 0301 basic medicine Skin Neoplasms Lymphocyte Activation Immunophenotyping 03 medical and health sciences Cell Movement Cell Line, Tumor Humans Lymphocyte Count Intraepithelial Lymphocytes Melanoma RC254-282 Cell Proliferation Clinical/Translational Cancer Immunotherapy Neoplasms. Tumors. Oncology. Including cancer and carcinogens Middle Aged Coculture Techniques Healthy Volunteers 3. Good health Phenotype Female Immunologic Memory Biomarkers
DOI: 10.1136/jitc-2020-002274 Publication Date: 2021-05-19T17:36:03Z
ABSTRACT
Background Gamma-delta (γδ) T lymphocytes are primed to potently respond pathogens and transformed cells by recognizing a broad range of antigens. However, adoptive immunotherapy with γδT has exhibited mixed treatment responses. Better understanding cell biology stratifying healthy donors for allogeneic therapy is clinically needed fully realize the therapeutic potential cells. Methods We examine 98 blood samples from measure their expansion capacity after zoledronate stimulation, test migration cytotoxic effector function expanded in 2D culture, 3D tumor spheroid patient-derived melanoma organoid assays. Results find that independent methods, gender, age HLA type. Basal levels Peripheral mononuclear (PBMC) correlate well expansion, vitro. Circulating lower expression PD-1, CTLA-4, Eomes, T-bet CD69, or higher IFN-γ production expand better. central memory phenotypes significantly more abundant good expanders. A cut-off level 0.82% PBMC stratifies versus poor sensitivity 97.78%, specificity 90.48% area under curve 0.968 individual. Donors Vδ2 Index Score have greater anti-tumor functions including migratory cytotoxicity. Conclusions Our results demonstrate interindividual circulating donors. Examination may be used select participate γδT-based immunotherapies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (42)
CITATIONS (17)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....